Xtrac for Psoriasis, Vitiligo and Atopic Dermatitis
XTRAC is the only FDA-cleared, clinically proven excimer laser that gets skin clear of psoriasis—and it works fast, with many patients seeing significant improvement and long-lasting remissions. Because XTRAC delivers a highly targeted, therapeutic beam of UVB light only to areas of the skin affected by psoriasis, healthy skin surrounding the lesions stays that way.
XTRAC clears the symptoms, prolongs the remission and returns skin to a clinically healthy state in record time. All of which means XTRAC delivers consistently predictable results so patients experience more good days of living than bad.
- Effective treatment—symptoms reduced generally in 10-12 treatment sessions
- Long-lasting relief—typically several months free of symptoms”
- Simple, painless treatment—sessions are very short
- Relief without messy creams and daily skin care regimen
- Covered by most major insurance companies, available by Rx
Scalp Psoriasis Can be Cleared. 95% XTRAC CLEAR.
Because of the shielding effect of hair, traditional UVB lamp therapy is not very effective against scalp psoriasis. However, studies have reported success in treating it with the [XTRAC] 308 nm excimer laser which generates a targeted beam of UVB light.
XTRAC allows for simple manual separation of the hair, provides good visualization of the psoriasis and permits rapid treatment so that a whole scalp can often be treated in less than 15 minutes.
Vitiligo is Not Forever. XTRAC for Even Skin
XTRAC treatments can minimize and, in many cases, even eliminate Vitligo depigmented patches. The XTRAC [308 nm] excimer laser delivers a targeted beam of UVB light and only the areas of skin affected by Vitiligo receive the laser energy.
Though the laser spot size measures only 18mm x 18mm, due to rapid exposure times, relatively large, discrete areas can be treated in just five to 10 minutes, which is much quicker than the duration of conventional phototherapy light sessions. And most importantly, XTRAC treatments achieve complete response rates faster in a higher proportion of patients.